[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603095":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":27,"locations":19,"responsibleParty":34,"collaborators":19,"id":36,"slug":19,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":19,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":19,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":57,"whyStopped":19,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":19},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ultrahypofractionation Phase","EXPERIMENTAL","MR-Guided Ultrahypofractionation",[13],"Radiation: MR-guided Irradiation",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","MR-guided Irradiation",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Rafael Martínez-Monge, M.D.","Clínica Universidad de Navarra","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":23,"role":24},"Luis Fuertes, M.D.",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Beatriz Ramos Aguirre, M.S.","CONTACT","+34 948255400","2772","ucicec@unav.es",{"type":35,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100603095",false,"NCT07132060","MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Selection criteria includes patients with unresectable and borderline resectable and medically inoperable pancreatic cancer that will receive neoadjuvant chemotherapy followed by chemoirradiation.\n* No prior radiation therapy to the target areas;\n* Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including neoadjuvant chemotherapy followed by chemoirradiation.\n* WBC equal or greater than 3500 mm\\^3; platelet count equal or greater than 135000 mm\\^3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n\nExclusion Criteria:\n\n* Inability to undergo an MRI scan","ALL","18 Years","80 Years",{"count":45,"type":46},30,"ESTIMATED","INTERVENTIONAL",[49],"NA","The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer",[52],"Pancreatic Cancer",[54,55,56],"MRI-guided irradiation","Dose escalation","Ultrahypofractionation","NOT_YET_RECRUITING","2025-08-20",{"date":60,"type":61},"2025-08-27","ACTUAL",{"date":63,"type":46},"2025-10-01",{"date":65,"type":46},"2030-06-30",{"name":5,"class":6}]